华领医药(02552.HK)倒跌16%创上市新低 无法保证治疗糖尿病新药明年次季可成功开发
华领医药(02552.HK)公布研发中dorzagliatin(HMS5552)的单药治疗III期临床研究24周核心初步结果显示,其有可能通过针对引起2型糖尿病的主要原因以治疗2型糖尿病,但无法保证该药可於明年次季可以成功开发。该股今天高开最多弹5.7%高见7.19元无以为继,掉头最多挫18.5%午後低见5.54元,创上市新低,现造5.73元,急挫16%,一向稀疏成交增至199万股,为逾五个月最多。
华领公布,旗下研发中的双重机制葡萄糖激(酉每)启动剂dorzagliatin(HMS5552)的单药治疗III期临床研究24周核心初步研究结果显示,该药有可能通过针对引起2型糖尿病的主要原因以治疗2型糖尿病,修复血糖传感、重塑血糖稳态,通过在胰岛、肝脏和肠道发挥作用,调节胰岛素、胰高糖素和GLP-1的分泌,促进血糖稳态平衡。不过,公司无法保证将於明年次季获得52周临床研究结果或可以成功开发或最终成功推出dorzagliatin。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.